News

Horizon Europe work programme admendments - changes for the Health Cluster & new Cancer Mission calls

Published on
| 2 years ago
Programmes
  • Health

The European Commission has published the amendments to the Horizon Europe main workprogramme.

The main changes for Cluster 1 - Health concern:

  • HORIZON-HLTH-2024-DISEASE-13-01: Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD)
  • HORIZON-HLTH-2024-CARE-14-01: Pre-commercial procurement for environmentally sustainable, climate neutral and circular health and care systems
  • HORIZON-HLTH-2024-DISEASE-12-01: European partnership for pandemic preparedness

These calls will open on 25 April 2024 with deadline to apply on 26 November 2024.


As part of the amendment, 6 new Cancer Mission call for proposals (2024) were published under the Missions work programme :

  • HORIZON-MISS-2024-CANCER-01-01: Use cases for the UNCAN.eu research data platform
  • HORIZON-MISS-2024-CANCER-01-02: Support dialogue towards the development of national cancer data nodes
  • HORIZON-MISS-2024-CANCER-01-03: Accessible and affordable tests to advance early detection of heritable cancers in European regions
  • HORIZON-MISS-2024-CANCER-01-04: Support a pragmatic clinical trial programme by cancer charities
  • HORIZON-MISS-2024-CANCER-01-05: Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer
  • HORIZON-MISS-2024-CANCER-01-06: An information portal for the European Cancer Patient Digital Centre

These calls are open since 18 April 2024 with deadline to apply on 18 September 2024.

Related news

myOverview

Sign up for personalised information

Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.

  • News in your domains
  • Event announcements
  • A personal dashboard
Sign up now

Only for stakeholders located in Flanders

Latest news

2049 articles available Browse all news
  • EIC

EIC Work Programme 2027 adopted

The 2027 work programme opens funding opportunities worth over €1.8 billion for strategic technologies and scaling up companies. The EIC work programme 2027 details the funding in six main schemes: EIC Pathfinder EIC Transition Advanced Innovation Challenges EIC Accelerator The EIC Strategic Technologies for Europe Platform (STEP) Scale Up EIC...

Read more
  • Defence
  • DIRS

Start2Def 2026 call open

The Start2Def 2026 selection process opened on 4 November 2026. Belgian startups and small SMEs can submit proof-of-concept ideas for one of two defence-related challenges.

Read more

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.